Pulmonary Arterial Hypertension Global Pipeline Review, H1 2018
Pulmonary Arterial Hypertension
Overview
Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema).
Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2989071-pulmonary-arterial-hypertension-pipeline-review-h1-2018
Top Companies mentioned
Acceleron Pharma Inc
Biogen Inc
Complexa Inc
Eli Lilly and Co
Galectin Therapeutics Inc
GlaxoSmithKline Plc
Insmed Inc
Insys Therapeutics Inc
Japan Tobacco Inc
Johnson & Johnson
Liquidia Technologies Inc
Pulmonary Arterial Hypertension Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, and Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 9, 8, 21, 39, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively..
Pulmonary Arterial Hypertension - Competitive Analysis
Key players are making innovative developments in Pulmonary Arterial Hypertension industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension.
The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Pulmonary Arterial Hypertension therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension.
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2989071-pulmonary-arterial-hypertension-pipeline-review-h1-2018
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by
Vivian Dsena
on Friday April 13 2018, 3:30 AM EST.
All trademarks acknowledged.
Filed under Uncategorized.
Comments and Trackbacks closed.
Follow responses:
RSS 2.0
